These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20571611)

  • 1. Cardiovascular outcome of an angiotensin II receptor blocker, candesartan, in Japan.
    Suzuki H; Araki R
    Drugs Today (Barc); 2010 Jun; 46(6):427-31. PubMed ID: 20571611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
    Ogihara T; Nakao K; Fukui T; Fukiyama K; Ueshima K; Oba K; Sato T; Saruta T;
    Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
    Ueshima K; Oba K; Yasuno S; Fujimoto A; Sato T; Fukiyama K; Azuma J; Ogihara T; Saruta T; Nakao K;
    Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
    Nakao K; Hirata M; Oba K; Yasuno S; Ueshima K; Fujimoto A; Ogihara T; Saruta T;
    Hypertens Res; 2010 Jun; 33(6):600-6. PubMed ID: 20379187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
    Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
    Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
    Meredith PA
    Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candesartan: widening indications for this angiotensin II receptor blocker?
    Mendis B; Page SR
    Expert Opin Pharmacother; 2009 Aug; 10(12):1995-2007. PubMed ID: 19563275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
    Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
    Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
    Fukui T; Rahman M; Hayashi K; Takeda K; Higaki J; Sato T; Fukushima M; Sakamoto J; Morita S; Ogihara T; Fukiyama K; Fujishima M; Saruta T;
    Hypertens Res; 2003 Dec; 26(12):979-90. PubMed ID: 14717341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
    Shiga T; Kasanuki H; Hagiwara N; Sumiyoshi T; Honda T; Haze K; Takagi A; Kawana M; Origasa H; Ogawa H;
    Blood Press; 2010 Dec; 19(6):359-65. PubMed ID: 20491606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
    Cernes R; Mashavi M; Zimlichman R
    Vasc Health Risk Manag; 2011; 7():749-59. PubMed ID: 22241949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
    Suzuki H; Kanno Y;
    Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candesartan for cardiovascular prevention in Japanese hypertensive patients with coronary heart disease.
    Staessen JA; Richart T; Birkenhäger WH
    Eur Heart J; 2009 May; 30(10):1164-6. PubMed ID: 19363059
    [No Abstract]   [Full Text] [Related]  

  • 17. Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
    Plosker GL; Keam SJ
    Pharmacoeconomics; 2006; 24(12):1249-72. PubMed ID: 17129078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of angiotensin II receptor antagonist on heart failure].
    Matsumori A
    Nihon Rinsho; 2004 Jan; 62(1):203-10. PubMed ID: 14737854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
    Jearnsujitwimol V; Eiam-Ong S; Kanjanabuch T; Wathanavaha A; Pansin P
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S188-95. PubMed ID: 17044472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.